Remicade denied by insurance? Appeal and win.
A denial of Remicade is the beginning of a process, not the end of your treatment. This TNF inhibitor is most often denied because the plan requires a biosimilar infliximab first, demands documented step therapy through conventional drugs, or finds the prior authorization criteria incompletely supported in the chart. These denials are frequently overturned when the appeal directly maps your diagnosis, prior failed therapies, and required safety labs to the plan's own published criteria.
Reviewed by the Apellica Appeals Team · Updated June 2026
Carrier names and logos are trademarks of their respective owners. Apellica is independent and not affiliated with any insurance carrier or carrier's appeal program.
Remicade (infliximab) is FDA approved for several immune-mediated inflammatory conditions. These include moderately to severely active Crohn disease in adults and children 6 years and older who have not responded adequately to conventional therapy, including fistulizing Crohn disease in adults. It is approved for moderately to severely active ulcerative colitis in adults and children 6 years and older. It is also approved for moderately to severely active rheumatoid arthritis, given in combination with methotrexate, and for active ankylosing spondylitis, active psoriatic arthritis, and chronic severe plaque psoriasis in adults who are candidates for systemic therapy.
Why Remicade gets denied
- Biosimilar-first or step-therapy policy: the plan requires a trial of a preferred infliximab biosimilar such as Inflectra, Renflexis, or Avsola, or another formulary TNF inhibitor, before the reference Remicade is covered.
- Conventional therapy not documented: the chart does not clearly show inadequate response, intolerance, or contraindication to required first-line treatments such as conventional Crohn or colitis therapy, methotrexate for rheumatoid arthritis, or NSAIDs for ankylosing spondylitis.
- Prior authorization criteria not fully met on paper: missing diagnosis confirmation, disease activity measures, or required safety screening such as latent TB and hepatitis B testing before the first infusion.
- Site-of-care restriction: the plan denies the hospital outpatient infusion setting and steers the infusion to a freestanding infusion center, home infusion, or a specific provider network.
What a winning appeal includes
- A confirmed diagnosis with the correct ICD-10 code (for example K50.- for Crohn disease, K51.- for ulcerative colitis, M05/M06 for rheumatoid arthritis, M45 for ankylosing spondylitis, M07.- for psoriatic arthritis, or L40.- for plaque psoriasis) and objective disease activity such as CDAI, DAS28, BASDAI, endoscopy, or inflammatory markers (CRP, ESR).
- A clear prior-therapy history listing each required drug or biosimilar tried, the dose, the duration, and the specific reason it failed, was not tolerated, or is contraindicated.
- A letter of medical necessity that quotes the plan's own published coverage criteria and maps each requirement line by line to documentation in the record.
- Completed baseline safety workup specific to infliximab, including latent tuberculosis screening and hepatitis B serology, which both supports medical necessity and removes a common reason for delay or denial.
How we approach the appeal
First identify the exact denial basis, because the path differs: a non-formulary or biosimilar denial is fought as a formulary or tier exception, while a clinical denial is fought as a prior authorization or medical necessity appeal. Pull the plan's published infliximab policy and answer each criterion in order, quoting its language back, for example its requirement of an inadequate response to conventional therapy or a trial of a preferred biosimilar, and attach the records that satisfy or exempt each point. If the denial stands after the written internal appeal, request a peer-to-peer review with the plan's medical director and, where eligible, escalate to an independent external review.
Remicade appeal letter template
Copy this Remicade appeal letter, fill in the brackets, and send it within your deadline. It is built on what overturns TNF inhibitor denials.
[Date] [Your name] · Member ID [ID] · Rx claim # [#] [Insurer or PBM] - Appeals Department Re: Appeal of Remicade denial I am appealing the denial of Remicade (infliximab). I request that the denial be overturned and Remicade approved. 1. The denial. [Insurer] denied Remicade stating, verbatim: "[paste the exact denial reason from your letter]." 2. Medical necessity. Remicade is medically necessary for my condition. First identify the exact denial basis, because the path differs: a non-formulary or biosimilar denial is fought as a formulary or tier exception, while a clinical denial is fought as a prior authorization or medical necessity appeal. Pull the plan's published infliximab policy and answer each criterion in order, quoting its language back, for example its requirement of an inadequate response to conventional therapy or a trial of a preferred biosimilar, and attach the records that satisfy or exempt each point. If the denial stands after the written internal appeal, request a peer-to-peer review with the plan's medical director and, where eligible, escalate to an independent external review. 3. Step-therapy or formulary exception (if that was the reason): I have tried and failed [preferred drug(s)], with pharmacy records attached, or the preferred alternative is contraindicated because [reason]. I request a formulary or step-therapy exception. 4. My request. Approve Remicade within the timeframe required by law. If the denial is upheld, please provide the specific criteria used, the reviewing clinician's credentials, and external-review instructions. Attached: prescriber letter of medical necessity, pharmacy and prior-trial records, and supporting clinical notes. Sincerely, [Your name]
Want it built and filed for you? Use the free generator, or have Apellica do it.
Internal appeals: 30 days pre-service, 60 days post-service, 72 hours urgent. File within 180 days of the denial.
$0 upfront. We assess fit first, then build and file the appeal for you.
- · The denial letter and your Explanation of Benefits (EOB)
- · Insurance ID, plan name, and the claim or prior-authorization number
- · Diagnosis with ICD-10 code and the prescriber's clinical notes
- · A record of treatments already tried and how they worked
Appealing a Remicade denial by insurer
The path depends on who manages your benefit. The most common:
Coverage runs through the pharmacy benefit. Appeal the coverage determination and, when the drug is non-formulary, file a formulary or tier exception with a provider attestation that covered alternatives are unsuitable.
Publishes detailed prior-authorization criteria. A denial usually means a criterion was not documented. Appeal through a coverage review, with a formulary exception for excluded drugs.
Administers many UnitedHealthcare and employer plans. Appeals and exceptions follow the plan's published PA criteria; expedited review exists for urgent cases.
Internal appeal first, then independent external review. Pre-service decisions are generally made within 30 days, urgent within 72 hours.
Internal appeals and external review; pharmacy denials often route through OptumRx criteria.
Independent state plans, so criteria vary. Match the appeal to your specific BCBS plan, internal appeal first, then external review.
Frequently asked questions
My insurer says I have to try a biosimilar like Inflectra or Avsola before Remicade. Can I still get Remicade?
Yes, this is the most common Remicade hurdle and it is appealable. If your prescriber documents a specific medical reason the reference product is needed, or you previously tried and failed or could not tolerate a required biosimilar, you can request a formulary exception. The appeal should quote the plan's step-therapy rule and explain in clinical terms why the preferred option is not appropriate for you.
Does it matter that Remicade is given as an IV infusion rather than a pill?
Yes, and it changes how the appeal is handled. Infused drugs are often covered under the medical benefit rather than the pharmacy benefit, and many plans add a site-of-care rule that steers the infusion to a freestanding center or home infusion. If you are denied over location rather than the drug itself, the appeal should address medical necessity for your infusion setting separately from approval of the drug.
What documents should my doctor include to give the appeal the best chance?
The strongest packets include the confirmed diagnosis with its ICD-10 code, objective disease activity measures, a complete list of prior therapies with doses, durations, and reasons they failed or were not tolerated, baseline tuberculosis and hepatitis B screening results, and a letter of medical necessity that maps each of these to the plan's own written criteria.
Remicade denied? We fight it for you.
$0 upfront. Two-minute intake. We confirm fit and reply within one business day with the right path for your situation.
Start Your AppealThis page provides general information about appeal strategy. It is not legal or medical advice. Apellica is not a law firm. Outcomes depend on documentation, plan terms, and timing.